Product Code: ETC071154 | Publication Date: Jun 2021 | Updated Date: Apr 2025 | Product Type: Report | |
Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
In Australia, the infectious disease biomarker testing market is witnessing rapid growth due to the increasing prevalence of infectious diseases and the need for early detection and accurate diagnosis. The demand for biomarker-based tests for infectious diseases such as HIV, hepatitis, and COVID-19 is fueling market expansion.
The Australia Infectious Disease Biomarker Testing market experiences significant growth driven by the need for accurate and timely diagnosis of infectious diseases. With the need for early detection, disease monitoring, and treatment optimization, there is a rising requirement for biomarker testing solutions that offer sensitivity, specificity, and rapid results. Moreover, the expansion of healthcare infrastructure and the emergence of new infectious agents further stimulate market expansion, driving the adoption of infectious disease biomarker testing products.
Challenges in the infectious disease biomarker testing market include assay sensitivity, specificity, and validation. Diagnostic companies must develop biomarker tests that can accurately detect infectious diseases, differentiate between pathogens, and provide actionable results while meeting regulatory requirements and clinical standards.
Government policies in the infectious disease biomarker testing market may focus on public health surveillance, disease prevention, and diagnostic accuracy. Regulations may be established to validate biomarker tests for accuracy, sensitivity, and specificity before clinical use. Additionally, government funding may support research and development efforts to identify new biomarkers and improve testing technologies for infectious diseases.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Infectious Disease Biomarker Testing Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Infectious Disease Biomarker Testing Market - Industry Life Cycle |
3.4 Australia Infectious Disease Biomarker Testing Market - Porter's Five Forces |
3.5 Australia Infectious Disease Biomarker Testing Market Revenues & Volume Share, By Form, 2021 & 2031F |
3.6 Australia Infectious Disease Biomarker Testing Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.7 Australia Infectious Disease Biomarker Testing Market Revenues & Volume Share, By End-users, 2021 & 2031F |
4 Australia Infectious Disease Biomarker Testing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia Infectious Disease Biomarker Testing Market Trends |
6 Australia Infectious Disease Biomarker Testing Market, By Types |
6.1 Australia Infectious Disease Biomarker Testing Market, By Product |
6.1.1 Overview and Analysis |
6.1.2 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Product, 2021-2031F |
6.1.3 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Assays, Kits and Reagents, 2021-2031F |
6.1.4 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Instruments, 2021-2031F |
6.1.5 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Services and Software, 2021-2031F |
6.2 Australia Infectious Disease Biomarker Testing Market, By Technology |
6.2.1 Overview and Analysis |
6.2.2 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Immunodiagnostics, 2021-2031F |
6.2.3 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Clinical Microbiology, 2021-2031F |
6.2.4 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By PCR, 2021-2031F |
6.2.5 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By INAAT, 2021-2031F |
6.2.6 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By DNA Sequencing and NGS, 2021-2031F |
6.2.7 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Other Technologies, 2021-2031F |
6.3 Australia Infectious Disease Biomarker Testing Market, By End-users |
6.3.1 Overview and Analysis |
6.3.2 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Physician Offices, 2021-2031F |
6.3.3 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Reference Laboratories, 2021-2031F |
6.3.4 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Hospitals, 2021-2031F |
6.3.5 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Academic and Research Institutes, 2021-2031F |
6.3.6 Australia Infectious Disease Biomarker Testing Market Revenues & Volume, By Others, 2021-2031F |
7 Australia Infectious Disease Biomarker Testing Market Import-Export Trade Statistics |
7.1 Australia Infectious Disease Biomarker Testing Market Export to Major Countries |
7.2 Australia Infectious Disease Biomarker Testing Market Imports from Major Countries |
8 Australia Infectious Disease Biomarker Testing Market Key Performance Indicators |
9 Australia Infectious Disease Biomarker Testing Market - Opportunity Assessment |
9.1 Australia Infectious Disease Biomarker Testing Market Opportunity Assessment, By Product, 2021 & 2031F |
9.2 Australia Infectious Disease Biomarker Testing Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.3 Australia Infectious Disease Biomarker Testing Market Opportunity Assessment, By End-users, 2021 & 2031F |
10 Australia Infectious Disease Biomarker Testing Market - Competitive Landscape |
10.1 Australia Infectious Disease Biomarker Testing Market Revenue Share, By Companies, 2024 |
10.2 Australia Infectious Disease Biomarker Testing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |